KOPRAN

Kopran Limited

Active Pharmaceutical Ingredients and finished-dose formulations manufacturer

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

kopran.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹271.15
Market cap
1,307 Cr
Stock P/E
52.3
P/B
2.47
Dividend yield
1.1%
ROE (FY26)
4.9%
ROCE (FY26)
6.6%
Operating margin (FY26)
6.5%
Debt / equity (FY26)
0.29
OCF / EBITDA (FY26)
107.7%
OCF / EBITDA (3Y)
72.6%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Kopran makes active pharmaceutical ingredients (APIs) and finished oral medicines (formulations), and supplies them to customers in more than 50 countries.

Company snapshot

87thBy market cap

Ranked among 119 companies in Pharmaceuticals.

What we see

Positives
  • ✓Debt-to-equity of 0.29x — the company is largely funded by its own money, not borrowed funds.
1 more signal from the filings.Sign in free to see them all

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales153 Cr159 Cr186 Cr139 Cr152 Cr166 Cr172 Cr135 Cr118 Cr194 Cr234 Cr154 Cr
Operating expenses (approx.)130 Cr135 Cr164 Cr121 Cr137 Cr146 Cr155 Cr121 Cr123 Cr177 Cr201 Cr138 Cr
EBITDA23 Cr24 Cr22 Cr18 Cr15 Cr20 Cr17 Cr14 Cr-5 Cr18 Cr33 Cr16 Cr
OPM %15.0%14.8%11.7%13.0%9.7%11.9%9.9%10.5%-4.5%9.1%14.1%10.3%
Other income0.13 Cr2 Cr10 Cr3 Cr0.99 Cr0.17 Cr3 Cr3 Cr0.03 Cr0.07 Cr0.09 Cr2 Cr
Interest2 Cr2 Cr3 Cr2 Cr2 Cr2 Cr3 Cr3 Cr2 Cr3 Cr3 Cr3 Cr
Depreciation3 Cr3 Cr4 Cr4 Cr4 Cr4 Cr4 Cr4 Cr4 Cr4 Cr5 Cr6 Cr
Profit before tax18 Cr21 Cr25 Cr15 Cr10 Cr14 Cr14 Cr10 Cr-12 Cr11 Cr25 Cr9 Cr
Tax %24.6%23.0%26.0%24.7%23.4%25.0%29.4%24.7%14.6%13.1%25.6%23.9%
Net profit14 Cr16 Cr19 Cr11 Cr7 Cr10 Cr10 Cr7 Cr-10 Cr9 Cr19 Cr7 Cr
EPS (₹)₹2.86₹3.28₹3.86₹2.30₹1.53—₹2.01₹1.54₹-2.06₹1.93₹3.91₹1.39

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales319 Cr315 Cr358 Cr359 Cr492 Cr478 Cr551 Cr615 Cr630 Cr681 CrSign in free for the trailing twelve months
Operating expenses (approx.)283 Cr284 Cr312 Cr313 Cr410 Cr390 Cr499 Cr540 Cr557 Cr619 CrSign in free for the trailing twelve months
EBITDA36 Cr30 Cr46 Cr47 Cr82 Cr87 Cr52 Cr74 Cr73 Cr62 CrSign in free for the trailing twelve months
OPM %11.3%9.7%12.9%13.0%16.6%18.3%9.4%12.1%11.6%9.1%Sign in free for the trailing twelve months
Other income11 Cr10 Cr3 Cr0.63 Cr18 Cr11 Cr3 Cr15 Cr4 Cr0.35 CrSign in free for the trailing twelve months
Interest14 Cr9 Cr9 Cr9 Cr6 Cr5 Cr6 Cr9 Cr9 Cr10 CrSign in free for the trailing twelve months
Depreciation8 Cr9 Cr9 Cr10 Cr10 Cr11 Cr13 Cr13 Cr16 Cr17 CrSign in free for the trailing twelve months
Profit before tax25 Cr23 Cr32 Cr28 Cr83 Cr82 Cr36 Cr68 Cr52 Cr34 CrSign in free for the trailing twelve months
Tax %19.6%10.5%24.1%25.7%26.1%25.4%24.5%24.6%25.8%25.1%Sign in free for the trailing twelve months
Net profit20 Cr20 Cr24 Cr21 Cr62 Cr61 Cr27 Cr51 Cr39 Cr26 CrSign in free for the trailing twelve months
EPS (₹)₹4.60₹4.75₹5.55₹4.86₹14.24₹13.77₹5.65₹10.57₹7.99₹5.33Sign in free for the trailing twelve months
Dividend payout %————10.5%10.6%53.1%28.4%0.0%56.3%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital43 Cr43 Cr43 Cr43 Cr43 Cr48 Cr48 Cr48 Cr48 Cr48 Cr
Reserves81 Cr101 Cr125 Cr146 Cr202 Cr378 Cr391 Cr443 Cr470 Cr482 Cr
Borrowings89 Cr82 Cr87 Cr78 Cr64 Cr72 Cr75 Cr99 Cr148 Cr153 Cr
Other liabilities85 Cr89 Cr97 Cr104 Cr130 Cr112 Cr135 Cr153 Cr178 Cr225 Cr
Total liabilities298 Cr315 Cr352 Cr371 Cr439 Cr611 Cr650 Cr743 Cr844 Cr908 Cr
Fixed assets (net)104 Cr104 Cr112 Cr111 Cr109 Cr148 Cr163 Cr179 Cr197 Cr337 Cr
CWIP5 Cr7 Cr17 Cr22 Cr37 Cr28 Cr56 Cr78 Cr99 Cr2 Cr
Investments0.05 Cr0.05 Cr2 Cr0.02 Cr0.05 Cr4 Cr0.06 Cr0.06 Cr0.06 Cr0.06 Cr
Loans & advances——4 Cr0.87 Cr0.47 Cr0.62 Cr0.74 Cr1 Cr8 Cr8 Cr
Inventories61 Cr71 Cr73 Cr88 Cr100 Cr150 Cr131 Cr138 Cr169 Cr164 Cr
Trade receivables73 Cr65 Cr87 Cr93 Cr120 Cr127 Cr163 Cr212 Cr215 Cr263 Cr
Cash & bank0.66 Cr0.44 Cr0.41 Cr0.83 Cr0.94 Cr6 Cr7 Cr8 Cr19 Cr0.68 Cr
Other assets55 Cr67 Cr56 Cr56 Cr71 Cr148 Cr130 Cr127 Cr136 Cr133 Cr
Total assets298 Cr315 Cr352 Cr371 Cr439 Cr611 Cr650 Cr743 Cr844 Cr908 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity16 Cr26 Cr25 Cr31 Cr60 Cr-34 Cr34 Cr43 Cr42 Cr67 Cr
Cash from investing-18 Cr-11 Cr-25 Cr-13 Cr-25 Cr-84 Cr-13 Cr-44 Cr-56 Cr-65 Cr
Cash from financing2 Cr-15 Cr-0.58 Cr-18 Cr-35 Cr123 Cr-20 Cr0.99 Cr26 Cr-21 Cr
Net cash flow-0.12 Cr-0.21 Cr-0.03 Cr0.42 Cr0.10 Cr5 Cr2 Cr0.69 Cr11 Cr-19 Cr
Free cash flow (OCF − Capex)-0.25 Cr14 Cr-6 Cr17 Cr36 Cr-76 Cr-27 Cr-13 Cr-17 Cr-0.37 Cr

Ratios

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %18.0%13.9%15.9%13.9%29.0%17.4%8.2%12.9%9.2%6.6%
ROE %16.0%14.2%14.3%11.1%25.1%14.3%6.2%10.4%7.4%4.9%
Debtor days847588948997107126124140
Inventory days142147136145137184148128154139
Days payable11012795901187699105108133
Cash conversion cycle11594129149108204156150170146
OCF / EBITDA %44.1%85.1%54.8%66.4%73.4%-38.4%65.7%58.1%57.4%107.7%
OCF / EBITDA % (3 years)——59.6%66.7%66.6%26.6%27.4%20.5%59.8%72.6%
Debt / equity0.710.570.510.410.260.170.170.200.290.29
Current ratio1.321.431.541.591.722.742.252.082.021.51
Net debt / EBITDA2.44—1.861.650.770.761.311.221.762.45